Acarbose + glibenclamide
Acarbose + glibenclamide has been studied in 1 paper since 2002: 1 trial in people. The newest paper, Jun 1, 2002: “The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia”.
See all 16 papers on acarbose + glibenclamide
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Acarbose plus glibenclamide treatment significantly reduced the mean increase in postprandial blood glucose levels (23.7+/-17.3 mg/dl)”
None of its findings points the other way.
- 1 lab in 1 country
- Human trial1
Studies in people
1 study gave acarbose + glibenclamide to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases postprandial blood glucose increase23.7 vs 58.4 (acarbose), 56.9 (glibenclamide), 101.6 (placebo) mg/dl mean increase; p<0.05 for all down: Decreases serum insulinAUC 243.5 vs 383.4 hr x microU/ml; p=0.02 down: Lowers the risk of hypoglycemia6 (29%) with glibenclamide vs 2 (10%) with acarbose plus glibenclamide | Randomized trial | 84 peoplePatient cohorts | Diabetes, nutrition & metabolism, Jun 1, 2002 |
What did studies of acarbose + glibenclamide find?
2Studies of acarbose + glibenclamide measured 2 outcomes: serum insulin and postprandial blood glucose increase.
Serum insulin
downin humans1
1 study
Serum insulin
downin humans1
Acarbose + glibenclamide decreases serum insulin in humans (compared with glibenclamide monotherapy) (AUC 243.5 vs 383.4 hr x microU/ml; p=0.02).
“Serum insulin levels (mean AUC(7.30-12 h)) observed with acarbose plus glibenclamide combination therapy were significantly lower”
Human trialcompared with glibenclamide monotherapyn = 84
Diabetes, nutrition & metabolism
Postprandial blood glucose increase
downin humans1
1 study
Postprandial blood glucose increase
downin humans1
Acarbose + glibenclamide decreases postprandial blood glucose increase in humans (compared with acarbose, glibenclamide or placebo alone) (23.7 vs 58.4 (acarbose), 56.9 (glibenclamide), 101.6 (placebo) mg/dl mean increase; p<0.05 for all).
“Acarbose plus glibenclamide treatment significantly reduced the mean increase in postprandial blood glucose levels (23.7+/-17.3 mg/dl)”
Human trialcompared with acarbose, glibenclamide or placebo alonen = 84
Diabetes, nutrition & metabolism
What is acarbose + glibenclamide linked with?
1Studies link acarbose + glibenclamide with hypoglycemia.
Hypoglycemia
downin humans1
1 study
Hypoglycemia
downin humans1
Acarbose + glibenclamide lowers the risk of hypoglycemia in humans (compared with glibenclamide alone) (6 (29%) with glibenclamide vs 2 (10%) with acarbose plus glibenclamide).
“6 (29%) hypoglycaemic episodes occurred with glibenclamide, 2 (10%) with acarbose plus glibenclamide and none with acarbose”
Human trialcompared with glibenclamide alonen = 84
Diabetes, nutrition & metabolism